Derrick Ferguson, DO
Critical Care Medicine · Bloomington, INNPI 1134656853
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (59.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 94.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $7,070 and has fallen 52.2% since, to $3,382 in 2025. Among critical care medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $315.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- Amgen$341
- GSK$118
- Pulmonx Corporation$51
- Inspire Medical Systems, Inc.$33
- Mylan Specialty L.p.$26
- plus $73 from 4 others
What the payments were for
- Travel & lodging$2,95627%
- Food & beverage$1,47513%
- Education$6,62560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 24 | $10,414 |
| Amgen | 3 | $341 |
| GSK | 1 | $118 |
| Pulmonx Corporation | 1 | $51 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Mylan Specialty L.p. | 1 | $26 |
| Bristol Myers Squibb | 1 | $23 |
| United Therapeutics Corporation | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,192
- ION$3,000
- RAYOS$1,023
- NUCALA$118
How this compares
$11,056 in reported general payments places this provider in the 90th percentile of 158 critical care medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 274 | $254,114 |
| Spiriva RespimatTiotropium Bromide | 87 | $61,917 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $36,409 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $25,958 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $25,957 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $23,344 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $15,214 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $15,192 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $14,120 |
| Roflumilast | 118 | $9,959 |
| Voriconazole | 11 | $9,472 |
| Varenicline Tartrate | 39 | $8,506 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 36 | $6,147 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 157 | $4,618 |
| Ventolin HfaAlbuterol Sulfate | 15 | $1,939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $118 | $318,629398 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 158 critical care medicine providers in Indiana.
Other critical care medicine in Bloomington
- Karen SayadBloomington$7K
- Vrushank PatelIndianapolis$142K
- Matthew KoscielskiSouth Bend$118K
- Christopher KnieseIndianapolis$44K
- Stanley NasrawayIndianapolis$34K
- Ismail Al-AniSouth Bend$25K
- Horia DraghiciuRichmond$21K
- Shashikumar GowdaTerre Haute$20K
- Laura RodriguezMerrillville$15K
- Ryan BoenteIndianapolis$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.